AMERICAN COLLEGE OF RADIOLOGY ONCOLOGIC IMAGING NETWORK

我们建议组织一个机构合作小组， 将组成美国放射学会的个人 肿瘤成像网络（ACROIN）。 ACROIN将开展临床试验 通过其委员会结构和征聘特设 参与者严格评估新兴和更稳定的成像 这些技术与癌症患者有关。 最后， ACROIN的目标是：提高患者的生存率;改善 通过减少诊断和治疗的侵入性，提高 患者的幸福感，通过更快的速度和确定性， 诊断和治疗;减少诊断和治疗的发病率; 加速将发现转化为临床技术; 将有价值的技术传播到临床实践中。阿克罗因 将通过几项战略实现这些目标，包括： 最重要的恶性肿瘤和技术;适当的组合 新兴技术和成熟技术之间的试验;使用 各种终点-从简单的准确性测试到 患者结局和成本效益，根据成熟度 技术;核心和广告之间灵活、广泛的协作 临时参与者，包括机构、科学家、工业界、付款人， 建立一个组织，旨在加快 制定和实施试验，并加快传播 他们的研究结果;并依赖于过去的广泛经验， 总部和生物统计中心进行高质量的 临床试验 ACROIN建立了广泛的委员会结构 履行其职能;确保42个领导的承诺 放射科，他们将努力成为核心 机构参与者;收到八个机构的合作信 其他合作团体-每个团体都指定了一名代表 到ACROIN;并收到了一些商业公司的承诺 和保险公司，他们将参与和支持ACROIN一旦它 是成立的。

We propose to organize a cooperative group of institutions and individuals that will comprise the American College of Radiology Oncologic Imaging Network (ACROIN). ACROIN will develop clinical trials through its committee structure and the recruitment of ad hoc participants to rigorously assess both emerging and more stable imaging technologies as they relate to patients with cancer. Ultimately, ACROIN's goals are to: increase patient survival; improve quality of life through reduced invasiveness of diagnosis and treatment; improve patients' sense of well-being through greater rapidity and certainty of diagnosis and treatment; reduce diagnostic and therapeutic morbidity; hasten the translation of discovery to clinical technology; and speed the diffusion of worthwhile technologies into clinical practice. ACROIN will accomplish these goals by several strategies, including: a focus on the most important malignancies and technologies; an appropriate mix of trials between emerging and mature technologies; evaluation using a variety of endpoints -from tests of simple accuracy to assessment of patient outcomes and cost-effectiveness, according to the maturity of the technology; flexible, broad-based collaboration between core and ad hoc participants, including institutions, scientists, industry, payors, and patients; establishment of an organization designed to speed the development and implementation of trials and hasten dissemination of their findings; and reliance on the extensive past experience of the Headquarters and Biostatistical Center in conducting high quality clinical trials. ACROIN has developed an extensive committee structure to fulfill its functions; secured the commitment of 42 leading departments of radiology that they will try to qualify as core institutional participants; received letters of collaboration from eight other cooperative groups - each of which has designated a representative to ACROIN; and received the promises of a number of commercial companies and insurers that they will participate in and support ACROIN once it is established.